USPTO Examiner BRAUN MADELINE E - Art Unit 1624

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18652164SOLID FORMS OF ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION AND METHODS OF USE THEREOFMay 2024August 2024Allow410NoNo
18184077QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONSMarch 2023May 2025Allow2631NoNo
18162990PHARMACEUTICAL COMPOSITIONS CONTAINING HEMP EXTRACT FOR ADMINISTRATION TO FELINES AND RELATED METHODSFebruary 2023June 2025Allow2940NoNo
18146756HYDRALAZINE COMPOSITIONS AND METHODSDecember 2022June 2024Allow1720NoNo
18065772STABLE FORMULATIONS OF SHR0302December 2022September 2024Allow2130NoNo
18049952AQUEOUS PHARMACEUTICAL COMPOSITIONS OF PROSTAGLANDINSOctober 2022June 2024Allow2020YesNo
17956553SK CHANNEL POSITIVE ALLOSTERIC MODULATORSSeptember 2022January 2025Allow2831NoNo
17956727FAPI DIMER COMPOUND, FAPI DIMER-BASED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENT FOR TUMOR DIAGNOSIS, AND PREPARATION METHOD AND USE THEREOFSeptember 2022February 2024Allow1720NoNo
17837619CRYSTALLINE FORMS OF ALDH2 MODULATORSJune 2022August 2024Allow2620YesNo
17714500TREATMENT OF ABERRANT FIBROBLAST PROLIFERATIONApril 2022March 2025Abandon3622YesNo
17697281PURIFICATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDSMarch 2022May 2025Allow3820YesNo
17615659HETEROAROMATIC ACETAMIDE DERIVATIVE, AND PREPARATION AND USE THEREOFDecember 2021June 2025Allow4211NoNo
17604732COMPOUNDS AND METHODS FOR THE TREATMENT OF PARASITIC DISEASESOctober 2021May 2025Allow4311NoNo
17601790NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAMEOctober 2021May 2025Allow4410NoNo
17441405COMPOUNDS FOR USE IN THE TREATMENT OF ADCY5-RELATED DYSKINESIASeptember 2021May 2025Abandon4401NoNo
17440319COMPOUND AND DIAGNOSTIC SYSTEM COMPRISING SAID COMPOUND FOR THE GUSTATORY DETECTION OF INFLAMMATIONS IN THE ORAL CAVITYSeptember 2021March 2025Abandon4201NoNo
17310996MODULATORS OF AMPA RECEPTOR SIGNALINGSeptember 2021March 2025Allow4321YesNo
17435668COMPOSITION OF LANOSTEROL PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOFSeptember 2021April 2025Allow4320NoNo
17310930BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOFAugust 2021February 2025Abandon4101NoNo
17431634COMPOSITIONS COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR USE IN TREATING MENTAL DISORDERSAugust 2021June 2024Abandon3400NoNo
17400795PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUPAugust 2021January 2025Abandon4201NoNo
17391364METHODS AND COMPOSITIONS FOR MODULATING SPLICINGAugust 2021November 2024Abandon3901NoNo
17391361METHODS AND COMPOSITIONS FOR MODULATING SPLICINGAugust 2021November 2024Abandon3901NoNo
17391620METHODS AND COMPOSITIONS FOR MODULATING SPLICINGAugust 2021May 2025Allow4621NoNo
17425495CRYSTAL FORM OF 1,2,3-TRIAZOLO[1,5-A]PYRAZINES DERIVATIVE AND PREPARATION METHOD FOR CRYSTAL FORMJuly 2021February 2025Abandon4310NoNo
17423545COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASE WITH MATRIX METALLOPROTEINASE INHIBITORSJuly 2021December 2024Abandon4101NoNo
17416086THERAPIES FOR SQUAMOUS CELL CARCINOMASJune 2021March 2025Abandon4510NoNo
17415681ANALOGUES OF PENTAMIDINE AND USES THEREFORJune 2021April 2025Allow4620YesNo
17312667PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOFJune 2021May 2025Allow4820NoNo
17299463CRYSTALLINE FORMS OF MULTICYCLIC COMPOUNDS AND USES THEREOFJune 2021January 2025Abandon4410NoNo
17299438COMPOSITIONS AND METHODS FOR CLEANING, DECONTAMINATION AND TREATING SUBJECTS EXPOSED TO CHEMICAL IRRITANTSJune 2021February 2025Allow4410YesNo
172991895-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGEJune 2021November 2024Allow4221YesNo
17299164HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORSJune 2021April 2025Allow4620NoNo
17309485COMPOSITION AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCERJune 2021May 2024Allow3610YesNo
17298409COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCERMay 2021January 2025Abandon4411NoNo
17297984PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDSMay 2021June 2025Allow4821NoNo
17330200HYDANTOIN DERIVATIVEMay 2021May 2024Allow3610YesNo
17295490APPLICATION OF CHIDAMIDEMay 2021January 2025Abandon4420NoNo
17058587THERAPEUTIC AGENT FOR TREATING DIFFUSE GASTRIC CANCERMay 2021June 2025Abandon5420YesNo
17293506MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCERMay 2021October 2024Allow4120NoNo
17293381USE OF DISULFIRAM AND OTHER COMPOUNDS TO TREAT CANCERS WITH LOSS OF CHROMOSOME 16Q AND/OR LOW EXPRESSION OF METALLOTHIONEIN PROTEINSMay 2021May 2025Allow4820YesNo
17288934NEW ALKOXYAMINOPYRIDINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONSApril 2021November 2024Abandon4310NoNo
17240969COMBINATION SEROTONIN SPECIFIC REUPTAKE INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST FOR REDUCING L-DOPA-INDUCED DYSKINESIAApril 2021December 2024Allow4421YesNo
17287861Benzimidazolone Derivatives, and Analogues Thereof, as IL-17 ModulatorsApril 2021December 2024Allow4431YesNo
17285973METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTSApril 2021September 2024Abandon4111NoNo
17232012ORGANOSILANES FOR THE TREATMENT OF INFECTIONSApril 2021August 2024Allow4011YesNo
17284816INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATIONApril 2021October 2024Allow4211YesNo
17284855INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATIONApril 2021July 2024Allow4020NoNo
17284545COMPOSITIONS AND METHODS FOR REDUCING CANCER STEM CELLSApril 2021June 2025Allow5030YesNo
17284436TLR7 AGONIST FOR TREATING COLORECTAL CANCER AND PHARMACEUTICAL COMBINATION THEREOFApril 2021September 2024Allow4121YesNo
17226640LEVOKETOCONAZOLE FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA AND PRIMARY ALDOSTERONISMApril 2021September 2024Allow4120YesNo
17282024COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASESApril 2021March 2025Allow4821YesNo
17280267SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORSMarch 2021July 2024Abandon4010NoNo
17209337COMPOSITION AND APPLICATION THEREOF AS ANTITUMOR DRUGMarch 2021July 2024Allow4020NoNo
17277099FULLERENES TO TREAT DISEASES AND CONDITIONSMarch 2021January 2024Abandon3410NoNo
17274265BRD4-JAK2 INHIBITORSMarch 2021April 2025Allow4930NoNo
17274287BRD4-JAK2 INHIBITORSMarch 2021August 2024Allow4120NoNo
17273745CANNABINOIDS FOR THE TREATMENT OF GRAM-POSITIVE INFECTIONS INCLUDING ANTIBIOTIC-RESISTANT BACTERIAL STRAINSMarch 2021December 2024Abandon4501NoNo
17272871NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIAMarch 2021December 2024Allow4521YesNo
17272413CD47 BLOCKADE WITH PARP INHIBITION FOR DISEASE TREATMENTMarch 2021August 2024Allow4220YesNo
17182715SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOFFebruary 2021July 2024Allow4120YesNo
17269908BISPHOSPHONATE DRUG CONJUGATESFebruary 2021March 2024Allow3710YesNo
17269959SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENTFebruary 2021April 2024Allow3810YesNo
17156853ARAMCHOL SALTSJanuary 2021September 2024Abandon4401NoNo
17049162METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATIONOctober 2020October 2024Abandon4810NoNo
16638704NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDSFebruary 2020June 2025Allow6061YesNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner BRAUN, MADELINE E - Prosecution Strategy Guide

Executive Summary

Examiner BRAUN, MADELINE E works in Art Unit 1624 and has examined 65 patent applications in our dataset. With an allowance rate of 66.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner BRAUN, MADELINE E's allowance rate of 66.2% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BRAUN, MADELINE E receive 1.58 office actions before reaching final disposition. This places the examiner in the 41% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BRAUN, MADELINE E is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +43.6% benefit to allowance rate for applications examined by BRAUN, MADELINE E. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 31.2% of applications are subsequently allowed. This success rate is in the 55% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 73.5% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Petition Practice

When applicants file petitions regarding this examiner's actions, 133.3% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 14.0% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.